TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06294834

Intervention type: OTHER
Group type: OTHER
Intervention: Part 1 of intervention A - Wheelchair skills training modules
Description: Clinicians will review a suite of training videos in a prescribed order that discuss motor learning principles, safe spotting, and how to complete 15 intermediate and advanced skills:~1. Opening/closing doors~2. getting over a gap~3. getting over a threshold~4. ascending a low curb~5. descending a low curb~6. ascending a high curb~7. descending a high curb~8. performing a stationary wheelie~9. descending a high curb in a wheelie position~10. descending a steep incline in a wheelie position and stopping~11. ascending stairs~12. descending stairs~13. completing a floor-to-chair transfer~14. car transfers~15. folding and unfolding wheelchair

Intervention type: OTHER
Group type: OTHER
Intervention: Part 1 of intervention A - Wheelchair skills training modules
Description: Clinicians will review a suite of training videos in a prescribed order that discuss motor learning principles, safe spotting, and how to complete 15 intermediate and advanced skills:~1. Opening/closing doors~2. getting over a gap~3. getting over a threshold~4. ascending a low curb~5. descending a low curb~6. ascending a high curb~7. descending a high curb~8. performing a stationary wheelie~9. descending a high curb in a wheelie position~10. descending a steep incline in a wheelie position and stopping~11. ascending stairs~12. descending stairs~13. completing a floor-to-chair transfer~14. car transfers~15. folding and unfolding wheelchair

Intervention type: OTHER
Group type: OTHER
Intervention: Part 1 of intervention A - Wheelchair skills training modules
Description: Clinicians will review a suite of training videos in a prescribed order that discuss motor learning principles, safe spotting, and how to complete 15 intermediate and advanced skills:~1. Opening/closing doors~2. getting over a gap~3. getting over a threshold~4. ascending a low curb~5. descending a low curb~6. ascending a high curb~7. descending a high curb~8. performing a stationary wheelie~9. descending a high curb in a wheelie position~10. descending a steep incline in a wheelie position and stopping~11. ascending stairs~12. descending stairs~13. completing a floor-to-chair transfer~14. car transfers~15. folding and unfolding wheelchair

Intervention type: OTHER
Group type: OTHER
Intervention: Part 1 of intervention A - Wheelchair skills training modules
Description: Clinicians will review a suite of training videos in a prescribed order that discuss motor learning principles, safe spotting, and how to complete 15 intermediate and advanced skills:~1. Opening/closing doors~2. getting over a gap~3. getting over a threshold~4. ascending a low curb~5. descending a low curb~6. ascending a high curb~7. descending a high curb~8. performing a stationary wheelie~9. descending a high curb in a wheelie position~10. descending a steep incline in a wheelie position and stopping~11. ascending stairs~12. descending stairs~13. completing a floor-to-chair transfer~14. car transfers~15. folding and unfolding wheelchair
Study: NCT04128072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Description: • Patients will receive mogamulizumab 1.0 mg/kg IV over at least 1 hour on Days 1, 8, 15 and 22 of the first 28 day treatment cycle (C1) and on Days 1 and 15 of subsequent 28 day cycle (C2).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Skin Electron Beam Therapy (TSEB)
Description: * After completion of C2, patients will be administered TSEB at a dose of 12 Gy in 8 fractions (4 fractions per week). TSEB will start 28 days (window of + 7 days) after mogamulizumab (C2 D1).~* In case of toxicity from mogamulizumab, the maximum delay permitted for the start of TSEB is 2 weeks.~* If recovery to at least grade 1 from toxicity exceeds the 2 weeks interval, please contact the medical monitor.~* Mogamulizumab is stopped during TSEB administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mogamulizumab (subsequent cycles post TSEB)
Description: • Mogamulizumab will be restarted at a dose of 1.0 mg/kg IV on Days 1, 8, 15 and 22 for cycle 3. Subsequent cycles will be administered as for C2.~Treatment with mogamulizumab will be continued until disease progression (PD) or the occurrence of another withdrawal criterion.
Study: NCT06415916

Intervention type: PROCEDURE
Intervention: Cardiac ultrasound
Description: Performed 5 times between 0 and 120 minutes

Intervention type: PROCEDURE
Intervention: Lung ultrasound
Description: Performed 5 times between 0 and 120 minutes
Study: NCT06336447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Group #1: Virtual Reality Headset
Description: Group 1 will be assigned to the Virtual Realtity Headset. Participants will wear the device for at least 10 minutes prior to the planned procedure. Subjects will receive standard procedure. The VR Headset will be removed 10 minutes after the planned procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 2 No Virtual Reality Headset
Description: Group 2 will receive standard care without the use of the Virtuality Reality Heaset.
Study: NCT06246136

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ELIOS
Description: Following cataract surgery, surgeon will proceed to ELIOS treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Competitor Device
Description: Following cataract surgery, surgeon will proceed to Competitor treatment.
Study: NCT04673630

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Single dose subcutaneous injection
Study: NCT05036434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab / Lenvatinib
Description: Pembrolizumab Plus Lenvatinib administration.
Study: NCT04766125

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Adverse event information
Description: All patients have access to the standard material about adverse events related to the surgery. One arm will additionally receive elaborated adverse event information from a nurse and a surgeon

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Adverse event information
Description: All patients have access to the standard material about adverse events related to the surgery. One arm will additionally receive elaborated adverse event information from a nurse and a surgeon
Study: NCT04688710

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Hypnosis (HYP)
Description: Self-Hypnosis (HYP) teaches skills people with MS can use to effectively self-manage symptoms related to fatigue. Recordings are designed to help participants learn new strategies for influencing fatigue and its effects on their lives. The Self-Hypnosis recordings will start with a relaxation hypnotic induction (e.g., Notice how with each breath, you are feeling more and more relaxed ...) followed by hypnotic suggestions (e.g., for experiencing more energy, improved sleep, more comfort or less pain, etc.). The goal of Self-Hypnosis is to change participant's experiences. To the extent that participants respond to the suggestions, participants would then get more control over their feelings of energy, sleep quality, and comfort levels.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Meditation (MM)
Description: Mindfulness Meditation (MM) teaches skills people with MS can use to effectively self-manage symptoms related to fatigue. Recordings are designed to help participants learn about a new way to live with chronic fatigue and new ways to relate to how fatigue may influence their thoughts, feelings, and behavior. The mindfulness techniques train the mind to non-judgmentally observe experience (e.g., symptoms of fatigue or pain, etc.) on a moment-to-moment basis, with an attitude of acceptance. The goal of Mindfulness Meditation is not to alter experiences, but rather to change how someone responds to their experiences. With practice, automatic, kneejerk reactions to symptoms are replaced with mindful choices about how best to respond to symptoms. This will lighten the load of living with the symptoms, moving participants in the valued direction of their choosing.
Study: NCT05273138

Intervention type: OTHER
Intervention: Blood sampling and skin biopsy
Description: Blood sampling and skin biopsy

Intervention type: OTHER
Intervention: Blood sampling and skin biopsy
Description: Blood sampling and skin biopsy
Study: NCT05356247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lausanne Trialogue Play Brief
Description: The brief treatment program will consist of an LTP family assessment with video feedback to caregivers to address family interaction patterns and child mental health. Families will participate in four sessions conducted online using the Zoom for Healthcare platform. In the first session, families will engage in a family assessment in different groupings that will be recoded on zoom and used later in the treatment. In the second session, taking place one week later, families will take part in a mini assessment to learn more about the difficulties of the child. In the third session, the clinical team will share videos of the family assessment to the parents and discuss the families strengths, concerns, and goals for moving forward. In the fourth session, taking place one month after the third session, families will participate in a check-in session, debriefing the family assessment.
Study: NCT05670990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Equine assisted therapy
Description: A structured program that has been developed under several years at Humlamaden horse farm, for further information see under the description of the experimental group.
Study: NCT06117644

Intervention type: DRUG
Intervention: Furmonertinib
Description: Furmonertinib 40 mg/tablet, 4 tablets, QD
Study: NCT06348862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listening to either Quran, Music, and or Natural sound
Description: Patients will be assigned into one of the four groups based on their preferences. These groups are people who will listen to either Quran, Music, Natural sound, and or nothing (control group).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listening to either Quran, Music, and or Natural sound
Description: Patients will be assigned into one of the four groups based on their preferences. These groups are people who will listen to either Quran, Music, Natural sound, and or nothing (control group).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listening to either Quran, Music, and or Natural sound
Description: Patients will be assigned into one of the four groups based on their preferences. These groups are people who will listen to either Quran, Music, Natural sound, and or nothing (control group).
Study: NCT05520944

Intervention type: DRUG
Intervention: ClorNovir® (Chlorpheniramine) 0.4% Nasal Spray
Description: Patients will have received treatment with ClorNovir® as prescribed by their physician at the approved dose per local prescribing information, as part of their COVID-19 clinical recovery.
Study: NCT06261320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesotherapy with mesocaine, thiocolchicoside, amitriptyline, magnesium pidolate
Description: 4 sessions of mesotherapy (mesocaine, thiocolchicoside, amitriptyline, magnesium pidolate), with intra-epidermal and intra-hypodermal technics.
Study: NCT04606316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given as intravenous (IV) infusion into a vein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given as intravenous (IV) infusion into a vein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given as intravenous (IV) infusion into a vein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab-Placebo
Description: Intravenous (IV) solution that has no therapeutic effect, used as a control in testing investigational drug. One dose is received prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab-Placebo
Description: Intravenous (IV) solution that has no therapeutic effect, used as a control in testing investigational drug. One dose is received prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given as intravenous (IV) infusion into a vein.
Study: NCT05839899

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone plus one dose Misoprostol
Description: Mifepristone 200mg PO, then 800 mcg of misoprostol 24-30 hours later
Study: NCT05357274

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic testing
Description: Data will be uploaded to a server where algorithms will be deployed that incorporate features related to treatment use and variables of airflow will allocate the care pathway into one of the 4 pathways. Treatment will be directed by this using a validated automated decision support system
Study: NCT05404373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normobaric Hyperoxia (NBO)
Description: NBO was inhaled as early as possible before revascularization, and inhaled for 1h/2h/4h according to different groups

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normobaric Hyperoxia (NBO)
Description: NBO was inhaled as early as possible before revascularization, and inhaled for 1h/2h/4h according to different groups

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normobaric Hyperoxia (NBO)
Description: NBO was inhaled as early as possible before revascularization, and inhaled for 1h/2h/4h according to different groups

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low flow oxygen
Description: immediately given oxygen inhalation at a ventilation rate of 1L/ min using a oxygen storage mask and keep giving oxygen for 4 hours.
Study: NCT05039151

Intervention type: BIOLOGICAL
Intervention: interstitial fluid sampling
Description: The sample will be taken via three small catheters (thinner than the catheters used for conventional infusions) under the skin in the abdomen. 1 to 10 ml of interstitial liquid will be collected. A sample will be taken on D1 and D2.

Intervention type: BIOLOGICAL
Intervention: interstitial fluid sampling
Description: The sample will be taken via three small catheters (thinner than the catheters used for conventional infusions) under the skin in the abdomen. 1 to 10 ml of interstitial liquid will be collected. A sample will be taken on D1 and D2.

Intervention type: BIOLOGICAL
Intervention: blood sampling
Description: A blood sample (3 x 5 ml EDTA tubes) will be taken simultaneously. A sample will be taken on D1 and D2

Intervention type: BIOLOGICAL
Intervention: blood sampling
Description: A blood sample (3 x 5 ml EDTA tubes) will be taken simultaneously. A sample will be taken on D1 and D2
Study: NCT06294834

Intervention type: OTHER
Group type: OTHER
Intervention: Part 2 of intervention A - Asynchronous feedback from a remote trainer
Description: Participants will practice of wheelchair skills paired with remote feedback. Participants will be reminded to practice once per week. The participant will practice any number of the 15 skills for a self-selected duration. Following each practice session, the participant will upload video(s) of the skills practiced and a session log, indicating any difficulties they encountered. The remote trainer will then review the video-recordings and reply to the participant with feedback.

Intervention type: OTHER
Group type: OTHER
Intervention: Part 2 of intervention A - Asynchronous feedback from a remote trainer
Description: Participants will practice of wheelchair skills paired with remote feedback. Participants will be reminded to practice once per week. The participant will practice any number of the 15 skills for a self-selected duration. Following each practice session, the participant will upload video(s) of the skills practiced and a session log, indicating any difficulties they encountered. The remote trainer will then review the video-recordings and reply to the participant with feedback.
Study: NCT05839899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone plus two doses Misoprostol
Description: Mifepristone 200mg PO, then 800 mcg misoprostol 24-30 hours later, then another 800 mcg misoprostol 4 hours after that
Study: NCT04833049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994 Oral Tablet
Description: TAK-994 tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]TAK-994 Intravenous Infusion
Description: \[14C\]TAK-994 intravenous infusion.
Study: NCT04606316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given as intravenous (IV) infusion into a vein.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Treatment of disease or injury by cutting, abrading, suturing, or otherwise physically changing body tissues and organs.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Treatment of disease or injury by cutting, abrading, suturing, or otherwise physically changing body tissues and organs.
Study: NCT06468527

Intervention type: DRUG
Group type: OTHER
Intervention: Diponecaftor
Description: Diponecaftor is a triple combination of DIR/POS/NES. The combination therapy will be administered orally during 8 weeks. The daily dose contains:~* DIR 300 mg/day~* POS 600 mg/day~* NES 10 mg/day

Intervention type: DRUG
Group type: OTHER
Intervention: Diponecaftor
Description: Diponecaftor is a triple combination of DIR/POS/NES. The combination therapy will be administered orally during 8 weeks. The daily dose contains:~* DIR 300 mg/day~* POS 600 mg/day~* NES 10 mg/day

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo once daily for 8 weeks. Oral administration.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo once daily for 8 weeks. Oral administration.
Study: NCT06009887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview
Description: Motivational interviewing is a collaborative speaking style to strengthen one's own motivation and commitment to change. Motivational interviewing is not a technique but a fundamental therapeutic style that does not try to make people change their behavior against their will. Proven to be effective in many areas of healthcare, motivational interviewing is widely used to help people resolve their indecision about change, explore their concerns, and set their own goals. The purpose of the motivational interviews conducted in the study is to increase the belief in normal and natural birth by enabling pregnant women to understand the factors that affect their low belief in normal birth, to take action for change and to believe in change, and to minimize the practices that cause medicalization of birth such as cesarean section by reducing medical birth beliefs.
Study: NCT06294834

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention B: Education on wheelchair provision
Description: Participants will be provided with access to web-based wheelchair provision education modules. When the content is viewed will be self-selected by participants. Participants will be asked to complete a feedback survey at the end of the modules. Participants will receive weekly reminders to complete the intervention until a feedback survey completed.

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention B: Education on wheelchair provision
Description: Participants will be provided with access to web-based wheelchair provision education modules. When the content is viewed will be self-selected by participants. Participants will be asked to complete a feedback survey at the end of the modules. Participants will receive weekly reminders to complete the intervention until a feedback survey completed.

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention B: Education on wheelchair provision
Description: Participants will be provided with access to web-based wheelchair provision education modules. When the content is viewed will be self-selected by participants. Participants will be asked to complete a feedback survey at the end of the modules. Participants will receive weekly reminders to complete the intervention until a feedback survey completed.

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention B: Education on wheelchair provision
Description: Participants will be provided with access to web-based wheelchair provision education modules. When the content is viewed will be self-selected by participants. Participants will be asked to complete a feedback survey at the end of the modules. Participants will receive weekly reminders to complete the intervention until a feedback survey completed.
Study: NCT05474313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP-3D package
Description: A package of support tools for accessing, adhering to, and monitoring PrEP use, including Alto Pharmacy delivery services, PrEP-3D mobile app, and home laboratory testing.
Study: NCT04833049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]TAK-994 Oral Suspension
Description: \[14C\]TAK-994 oral suspension.
Study: NCT05258565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV tPA (Activase)
Description: Any patients eligible came with acute ischemic stroke with or without COVID-19 infection within the time window for thrombolytic therapy (within 4 hours of onset)
Study: NCT05474313

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard of Care
Description: Participants are given local standard of care navigation for initiation of PrEP
Study: NCT04960332

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena
Description: RCT (no blinding) where the patients will be randomized to wound closure with staples and either Negative Pressure Wound Therapy (PREVENA PLUS™ Incision Management System) for 7 days or a conventional wound dressing.
Study: NCT05827562

Intervention type: DIAGNOSTIC_TEST
Intervention: flow cytometry
Description: Levels of circulating and synovial fluid CD4+ and CD4- T cells expressing CD8αα and CD8αβ will be assessed by flow cytometry using fluorochrome-labelled monoclonal antibodies against CD3, CD4, CD8α and CD8β surface markers. Levels of the following cells will be assessed:~1. CD3+CD4-CD8αα+~2. CD3+CD4-CD8α+CD8βlow~3. CD3+CD4-CD8α+CD8βhigh~4. CD3+CD4+CD8αβhigh~5. CD3+CD4+CD8αα+

Intervention type: DIAGNOSTIC_TEST
Intervention: flow cytometry
Description: Levels of circulating and synovial fluid CD4+ and CD4- T cells expressing CD8αα and CD8αβ will be assessed by flow cytometry using fluorochrome-labelled monoclonal antibodies against CD3, CD4, CD8α and CD8β surface markers. Levels of the following cells will be assessed:~1. CD3+CD4-CD8αα+~2. CD3+CD4-CD8α+CD8βlow~3. CD3+CD4-CD8α+CD8βhigh~4. CD3+CD4+CD8αβhigh~5. CD3+CD4+CD8αα+